Pharmacokinetics of a single, large dose of cholecalciferol

Marium Ilahi, Laura AG Armas, Robert P. Heaney

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Background: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. Objective: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. Design: One group (30 subjects) was supplemented with a single oral dose of 100 000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. Results: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (±SD) baseline of 27.1 ± 7.7 ng/mL to a concentration maximum of 42.0 ± 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 ± 0.80 ng/mL during 4 mo. Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials. gov as #NCT00473239.

Original languageEnglish (US)
Pages (from-to)688-691
Number of pages4
JournalAmerican Journal of Clinical Nutrition
Volume87
Issue number3
StatePublished - Mar 1 2008

Fingerprint

25-hydroxycholecalciferol
Calcifediol
cholecalciferol
Cholecalciferol
pharmacokinetics
Pharmacokinetics
dosage
mouth
Serum
barbiturates
anticonvulsants
Control Groups
Barbiturates
milk consumption
Kidney Diseases
liver diseases
Solar System
vitamin D
kidney diseases
Vitamin D

Keywords

  • 25-hydroxyvitamin D
  • Calcidiol
  • Calcium
  • Cholecalciferol
  • Hydroxycholecalciferol
  • Therapeutic use
  • Vitamin D

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Pharmacokinetics of a single, large dose of cholecalciferol. / Ilahi, Marium; Armas, Laura AG; Heaney, Robert P.

In: American Journal of Clinical Nutrition, Vol. 87, No. 3, 01.03.2008, p. 688-691.

Research output: Contribution to journalArticle

Ilahi, Marium ; Armas, Laura AG ; Heaney, Robert P. / Pharmacokinetics of a single, large dose of cholecalciferol. In: American Journal of Clinical Nutrition. 2008 ; Vol. 87, No. 3. pp. 688-691.
@article{a7039f77e81c460a81d196326c8c6494,
title = "Pharmacokinetics of a single, large dose of cholecalciferol",
abstract = "Background: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. Objective: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. Design: One group (30 subjects) was supplemented with a single oral dose of 100 000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. Results: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (±SD) baseline of 27.1 ± 7.7 ng/mL to a concentration maximum of 42.0 ± 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 ± 0.80 ng/mL during 4 mo. Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials. gov as #NCT00473239.",
keywords = "25-hydroxyvitamin D, Calcidiol, Calcium, Cholecalciferol, Hydroxycholecalciferol, Therapeutic use, Vitamin D",
author = "Marium Ilahi and Armas, {Laura AG} and Heaney, {Robert P.}",
year = "2008",
month = "3",
day = "1",
language = "English (US)",
volume = "87",
pages = "688--691",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of a single, large dose of cholecalciferol

AU - Ilahi, Marium

AU - Armas, Laura AG

AU - Heaney, Robert P.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. Objective: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. Design: One group (30 subjects) was supplemented with a single oral dose of 100 000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. Results: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (±SD) baseline of 27.1 ± 7.7 ng/mL to a concentration maximum of 42.0 ± 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 ± 0.80 ng/mL during 4 mo. Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials. gov as #NCT00473239.

AB - Background: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. Objective: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. Design: One group (30 subjects) was supplemented with a single oral dose of 100 000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. Results: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (±SD) baseline of 27.1 ± 7.7 ng/mL to a concentration maximum of 42.0 ± 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 ± 0.80 ng/mL during 4 mo. Conclusions: Cholecalciferol (100 000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be ≤2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials. gov as #NCT00473239.

KW - 25-hydroxyvitamin D

KW - Calcidiol

KW - Calcium

KW - Cholecalciferol

KW - Hydroxycholecalciferol

KW - Therapeutic use

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=40549104752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549104752&partnerID=8YFLogxK

M3 - Article

C2 - 18326608

AN - SCOPUS:40549104752

VL - 87

SP - 688

EP - 691

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 3

ER -